MarkGGoldsteinMDFACP

Oncology • Bethesda, MD

Hematologic Oncology

Hematology/Oncology in Maryland

Join to view full profile

Dr. Goldstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Goldstein's full profile

Already have an account?

Office
6410 Rockledge Dr
660
Bethesda, MD 20817
Phone+1 301-571-0019

Fax+1 301-571-0988
Is this information wrong?

Education & Training

Yale UniversityMD, Bone Marrow Transplant externship, 2008 - 2008
University of ConnecticutFellowship, Hematology and Medical Oncology, 2005 - 2008
University of ConnecticutResidency, Internal Medicine, 2002 - 2005
St. George's University School of MedicineClass of 2002

Certifications & Licensure

MD State Medical License 2008 - 2024
DC State Medical License 2020 - 2024
CT State Medical License 2005 - 2022
PA State Medical License 2009 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Certified Physician MD Anderson Cancer Center, 2016-2020
ASH Advocacy Leadership Institute American Society of Hematology, 2019
Fellow of the American College of Physicians American College of Physicians, 2015
Most Compassionate Doctor American Registry, 2010
Chief Fellow, Hematology/Oncology University of Connecticut, 2007
Commendation for Excellence in Patient Care University of Connecticut, 2002-2003
President AED Premedical National Honor Society, 1995-1997
Research Grant Howard Hughes Medical Institute, 1996
Join now to see all

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2021 Aug 09
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Thymoma developing 30 years after mantle radiation for Hodgkin's lymphoma.
Mark G. Goldstein, Robert Siegel> ;Connecticut Medicine. 2009 Oct 1
33 citations
Heat-shock proteins in infection-mediated inflammation-induced tumorigenesis
Mark G. Goldstein, Zihai Li> ;Journal of Hematology & Oncology. 2009 Jan 30

Grant Support

Howard Hughes Medical Institute Undergraduate Research GrantUniversity of Georgia1996

Professional Memberships

American College of Physicians - ACP
Fellow
American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
European Society of Medical Oncology (ESMO)
Member
MedChi
Member
MDCSCO
Member

Hospital Affiliations

Frederick HealthFrederick, Maryland
Holy Cross Germantown HospitalGermantown, Maryland
Adventist Healthcare Shady Grove Medical CenterRockville, Maryland